Abstract
Resistance to the current first-line antimalarials threatens the control of malaria caused by the protozoan parasite Plasmodium falciparum and underscores the urgent need for new drugs with novel modes of action. Here, we present the argument that the parasite’s chloroquine resistance transporter (PfCRT) constitutes a promising target to combat multidrug-resistant malaria.
MeSH terms
-
Antimalarials / pharmacology*
-
Antimalarials / therapeutic use
-
Chloroquine / pharmacology
-
Chloroquine / therapeutic use
-
Drug Resistance*
-
Evolution, Molecular
-
Humans
-
Malaria, Falciparum / drug therapy
-
Malaria, Falciparum / parasitology
-
Membrane Transport Proteins / genetics*
-
Membrane Transport Proteins / metabolism*
-
Mutant Proteins / genetics
-
Mutant Proteins / metabolism
-
Mutation, Missense
-
Plasmodium falciparum / drug effects*
-
Plasmodium falciparum / enzymology
-
Protozoan Proteins / genetics*
-
Protozoan Proteins / metabolism*
-
Quinolines / pharmacology
-
Quinolines / therapeutic use
Substances
-
Antimalarials
-
Membrane Transport Proteins
-
Mutant Proteins
-
PfCRT protein, Plasmodium falciparum
-
Protozoan Proteins
-
Quinolines
-
Chloroquine
-
piperaquine